Cost-Effectiveness Analysis of Fluocinolone Acetonide Intravitreal (FAI) Implant for Chronic Noninfectious Uveitis Affecting the Posterior Segment of the Eye (NIU-PS) in China
Open Access
- 27 April 2024
- journal article
- research article
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 13 (6) , 1757-1772
Abstract
Introduction Chronic non-infectious uveitis affecting the posterior segment (NIU-PS), which can be recurrent and persistent for numerous years, mainly affects people of working age and significantly increases the risk of visual impairment. This study aimed to investigate the cost-effectiveness of fluocinolone acetonide intravitreal (FAI) implant in the treatment of patients with chronic NIU-PS from the Chinese healthcare perspective. Methods A Markov model with a 2-week cycle was constructed from the perspective of the Chinese healthcare system over a lifetime time horizon. The model consists of four health states: on-treatment, treatment failure, blindness, and death. The outcomes for effectiveness were based on the Chinese real-world study (RWS). Utilities and mortality rates were derived from published literature and standard sources. Costs were determined from the MENET website, prices of medical service items at local providers, published literature, and expert surveys. Outcomes were measured in quality-adjusted life years (QALYs). Sensitivity analyses were performed to account for the impact of uncertainty. Results It was estimated that in the base case, the FAI implant provided 0.43 incremental QALYs compared with the limited current practice (LCP) at an additional cost of $7503.72 (¥50,575.05), resulting in an incremental cost-effectiveness ratio (ICER) of $17,373.49 (¥117,097.33) per QALY gained. Parameters related to utility emerged as the primary influencers on the outcomes. In probabilistic sensitivity analysis (PSA), considering the willingness-to-pay (WTP) threshold of $19,072 (¥128,547) and $38,145 (¥257,094), the FAI implant had 67.70% and 99.50% probability of being cost-effective, respectively. As demonstrated in the scenario analysis, if the FAI implant aligns its price reduction with the average rate from the 2023 negotiation of the National Reimbursement Drug List (NRDL), it would result in lower costs and represent an absolute advantage. Conclusions The FAI implant, which can effectively reduce the recurrence rate and maintain the incremental costs within the WTP limit, is likely to be cost-effective in treating chronic NIU-PS in China.Keywords
Funding Information
- Jiangsu Funding Program for Excellent Postdoctoral Talent (2023ZB105)
- Ocumension Therapeutics Co., Ltd., Shanghai, China
This publication has 30 references indexed in Scilit:
- Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior SegmentOphthalmology, 2019
- Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious UveitisOphthalmology, 2018
- Burden of Low Vision and Blindness in Chinese Elder Popullation:Data from Field SurveyValue in Health, 2016
- Corticosteroid implants for chronic non-infectious uveitisCochrane Database of Systematic Reviews, 2016
- Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or PanuveitisOphthalmology, 2015
- Multicenter Study of Intravitreal Dexamethasone Implant in Noninfectious Uveitis: Indications, Outcomes, and Reinjection FrequencyAmerican Journal of Ophthalmology, 2014
- Cost-Effectiveness of Fluocinolone Acetonide Implant versus Systemic Therapy for Noninfectious Intermediate, Posterior, and PanuveitisOphthalmology, 2014
- Treatment with Repeat Dexamethasone Implants Results in Long-Term Disease Control in Eyes with Noninfectious UveitisOphthalmology, 2014
- Pharmacoeconomics of Pharmacogenetics within the Context of General Health Technology Assessments2013
- Incidence and prevalence of uveitis in Northern California The Northern California Epidemiology of Uveitis StudyOphthalmology, 2004